CN102821765A - 改良神经传导速度的方法和组合物 - Google Patents

改良神经传导速度的方法和组合物 Download PDF

Info

Publication number
CN102821765A
CN102821765A CN2011800145791A CN201180014579A CN102821765A CN 102821765 A CN102821765 A CN 102821765A CN 2011800145791 A CN2011800145791 A CN 2011800145791A CN 201180014579 A CN201180014579 A CN 201180014579A CN 102821765 A CN102821765 A CN 102821765A
Authority
CN
China
Prior art keywords
hydrogen
alkyl
phenyl
formula
xenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800145791A
Other languages
English (en)
Chinese (zh)
Inventor
T·D·姆卡蒂
A·R·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Spinifex Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinifex Pharmaceuticals Pty Ltd filed Critical Spinifex Pharmaceuticals Pty Ltd
Priority to CN201711036658.8A priority Critical patent/CN107744519A/zh
Publication of CN102821765A publication Critical patent/CN102821765A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800145791A 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物 Pending CN102821765A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711036658.8A CN107744519A (zh) 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29637510P 2010-01-19 2010-01-19
US61/296,375 2010-01-19
PCT/AU2011/000051 WO2011088504A1 (en) 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711036658.8A Division CN107744519A (zh) 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物

Publications (1)

Publication Number Publication Date
CN102821765A true CN102821765A (zh) 2012-12-12

Family

ID=44306296

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800145791A Pending CN102821765A (zh) 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物
CN201711036658.8A Pending CN107744519A (zh) 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711036658.8A Pending CN107744519A (zh) 2010-01-19 2011-01-19 改良神经传导速度的方法和组合物

Country Status (10)

Country Link
US (1) US9095587B2 (enExample)
EP (1) EP2525795B1 (enExample)
JP (2) JP6232184B2 (enExample)
CN (2) CN102821765A (enExample)
AU (1) AU2011207104C1 (enExample)
CA (1) CA2787173C (enExample)
ES (1) ES2560327T3 (enExample)
NZ (1) NZ601383A (enExample)
WO (1) WO2011088504A1 (enExample)
ZA (1) ZA201205375B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003244A (zh) * 2010-07-21 2013-03-27 西芬克斯医药有限公司 四氢异喹啉衍生物的盐和溶剂合物
CN105358532A (zh) * 2013-07-08 2016-02-24 诺华股份有限公司 杂环化合物和它们的使用方法
CN106478502A (zh) * 2015-08-29 2017-03-08 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2018224037A1 (zh) * 2017-06-09 2018-12-13 南京明德新药研发股份有限公司 作为at2r受体拮抗剂的羧酸衍生物
WO2020088677A1 (zh) * 2018-11-02 2020-05-07 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10391331B2 (en) * 2011-03-29 2019-08-27 Biolyst, Llc. Systems and methods for use in treating sensory impairment
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
PT2807171T (pt) 2012-01-25 2020-11-03 Novartis Ag Compostos heterocíclicos e métodos para a sua utilização
NZ627560A (en) 2012-01-25 2016-08-26 Novartis Ag Heterocyclic piperazine compounds and methods for their use
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
WO2016142867A1 (en) 2015-03-12 2016-09-15 Novartis Ag Heterocyclic compounds and methods for their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091390A (en) * 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
CN101087619A (zh) * 2004-12-24 2007-12-12 昆士兰大学 治疗或预防的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132544C (en) * 1992-04-13 2005-10-18 Frank Carey Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091390A (en) * 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
CN101087619A (zh) * 2004-12-24 2007-12-12 昆士兰大学 治疗或预防的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARYK.VANATTEN,ET AL.: ""A Novel Series of Selective, Non-Peptide Inhibitors of Angiotensin I1 Binding to the AT2 Site"", 《JOURNAL OF MEDICAL CHEMISTRY》 *
SYLVESTER KLUTCHKO, ET AL.: ""TETRAHYDROISOQUINOLINE DERIVATIVES WITH AT2-SPECIFIC ANGIOTENSINII RECEPTOR BINDING INHIBITORY ACTIVITY"", 《BIOORGMIC & MEDICINAL CHEMISRTY LETTERS》 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003244B (zh) * 2010-07-21 2016-04-20 诺华股份有限公司 四氢异喹啉衍生物的盐和溶剂合物
CN105777636A (zh) * 2010-07-21 2016-07-20 诺华股份有限公司 四氢异喹啉衍生物的盐和溶剂合物
CN103003244A (zh) * 2010-07-21 2013-03-27 西芬克斯医药有限公司 四氢异喹啉衍生物的盐和溶剂合物
CN105358532B (zh) * 2013-07-08 2019-07-23 诺华股份有限公司 杂环化合物和它们的使用方法
CN105358532A (zh) * 2013-07-08 2016-02-24 诺华股份有限公司 杂环化合物和它们的使用方法
CN106478502A (zh) * 2015-08-29 2017-03-08 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
CN107922340A (zh) * 2015-08-29 2018-04-17 上海翰森生物医药科技有限公司 1,2,3,4‑四氢异喹啉衍生物、其制备方法和应用
WO2017036318A1 (zh) * 2015-08-29 2017-03-09 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
CN107922340B (zh) * 2015-08-29 2020-07-10 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2018224037A1 (zh) * 2017-06-09 2018-12-13 南京明德新药研发股份有限公司 作为at2r受体拮抗剂的羧酸衍生物
CN110914243A (zh) * 2017-06-09 2020-03-24 山东丹红制药有限公司 作为at2r受体拮抗剂的羧酸衍生物
US11021445B2 (en) 2017-06-09 2021-06-01 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as AT2R receptor antagonist
AU2018279669B2 (en) * 2017-06-09 2020-05-28 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as at AT2R receptor antagonist
AU2018279669B8 (en) * 2017-06-09 2020-10-15 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as at AT2R receptor antagonist
AU2018279669A8 (en) * 2017-06-09 2020-10-15 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as at AT2R receptor antagonist
CN110914243B (zh) * 2017-06-09 2023-02-28 山东丹红制药有限公司 作为at2r受体拮抗剂的羧酸衍生物
WO2020088677A1 (zh) * 2018-11-02 2020-05-07 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
JP2021534143A (ja) * 2018-11-02 2021-12-09 シャンドン ダンホン ファーマスーティカル カンパニー リミテッドShandong Danhong Pharmaceutical Co., Ltd. アンジオテンシンｉｉ２型受容体拮抗薬の塩形、結晶形及びその製造方法
JP7089636B2 (ja) 2018-11-02 2022-06-22 シャンドン ダンホン ファーマスーティカル カンパニー リミテッド アンジオテンシンｉｉ２型受容体拮抗薬の塩形、結晶形及びその製造方法
CN112585120B (zh) * 2018-11-02 2022-11-11 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
CN112585120A (zh) * 2018-11-02 2021-03-30 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法

Also Published As

Publication number Publication date
HK1176554A1 (en) 2013-08-02
AU2011207104C1 (en) 2015-10-08
JP2016155846A (ja) 2016-09-01
AU2011207104B2 (en) 2015-07-02
ES2560327T3 (es) 2016-02-18
ZA201205375B (en) 2013-09-25
AU2011207104A1 (en) 2012-07-26
EP2525795B1 (en) 2015-10-21
EP2525795A1 (en) 2012-11-28
CA2787173A1 (en) 2011-07-28
NZ601383A (en) 2014-07-25
CA2787173C (en) 2018-05-01
US9095587B2 (en) 2015-08-04
EP2525795A4 (en) 2013-07-24
JP6232184B2 (ja) 2017-11-15
WO2011088504A1 (en) 2011-07-28
US20130131103A1 (en) 2013-05-23
JP2013517300A (ja) 2013-05-16
CN107744519A (zh) 2018-03-02

Similar Documents

Publication Publication Date Title
CN102821765A (zh) 改良神经传导速度的方法和组合物
Catterall et al. Local anesthetics
Gristwood et al. Levobupivacaine: a new safer long acting local anaesthetic agent
JP4097285B2 (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
TWI353835B (en) Novel methods for identifying improved, non-sedati
JP2003522785A (ja) 眼痛の処置方法
KR20220132666A (ko) 지속성 국소 마취용 네오삭시톡신 조합 제형
WO2005030221A1 (ja) 加齢黄斑変性治療剤
JPH11501282A (ja) コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体
PT98895A (pt) Processo de preparacao de composicoes farmaceuticas a base de agentes bloqueadores dos canais de calcio em particular diltiazem verapamil,fostedil e di-hidropiridinas
KR20010021854A (ko) 말초 작용성 항소양성 아편제
JP6682533B2 (ja) 多汗症を治療するための方法
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
EP0968715B1 (en) Loratadine for use as an antiarrhymthmic
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
Corletto et al. Pharmacological treatment of pain
HK1176554B (en) Methods and compositions for improved nerve conduction velocity
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
Mamatha Comparative study between dexmedetomidine and midazolam in inducing conscious sedation in patient undergoing cataract surgery
Woelfel Neuromuscular Blocking Agents
Manjunath A Comparative Evaluation of Intravenous Dexmedetomidine and Oral Clonidine in Attenuating the Rise in Intra Ocular Pressure Following Administration of Suxamethonium, Laryngoscopy and Intubation
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
Eldin Anesthetic Management Of Patients With Myopathies
HRISHI MD (Anaesthesiology)
Swetha A Comparative Clinical Study of Intravenous Esmolol and Nitroglycerin for Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation in Patients Undergoing Elective Surgery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151228

Address after: Basel

Applicant after: Novartis Ag

Address before: Vitoria Australia

Applicant before: Spinifex Pharmaceuticals Pty Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121212